Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

ConditionAdjuvant Chemotherapy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age19+

SponsorHK inno.N Corporation

About this trial

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age over 19 at the time of obtaining the informed consent form

Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery

ECOG 0 or 1

Scheduled to RO or R1 resection

Disqualifiers

FOLFIRINOX contraindications among the drug approval requirements

Palliative Therapy

Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX

Trial population

110

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Disease-free survival

Duration of survival before pancreatic cancer recurrence or death

Time frame

Day 1 to Week 88

Secondary outcomes

Overall survival

Duration of overall survival

Time frame

Day 1 to Week 88

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

HK inno.N Corporation

Lead sponsor

Source ClinicalTrials.gov

Apply now